Intellia Therapeutics Share Price Today

Intellia Therapeutics Q3 Results: Loss widens to $0.91, sales fall 48%

Intellia Therapeutics reported a Q3 loss of $0.91 per share, missing the $0.80 estimate. Quarterly sales fell 48.03% YoY to $7.163 million, below the $10.461 million forecast. The loss per share improved slightly from $(0.92) in the same quarter last year. Revenue missed analyst expectations by 31.53%, indicating a significant shortfall.

Intellia Therapeutics completes enrollment in Phase 3 MAGNITUDE-2 trial

Intellia Therapeutics completed enrollment in the Phase 3 MAGNITUDE-2 trial. The study evaluates nex-z for treating hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN). Nex-z is an in vivo CRISPR-based therapy designed to inactivate the TTR gene in the liver. The therapy aims to provide potentially lifelong TTR protein reduction after a one-time treatment.

Intellia Therapeutics logs $106.6 million net loss in Q2FY26

Intellia Therapeutics reported a net loss of $106.6 million in Q2FY26, up 5.2% YoY. LVOSI Phase 3 Halo trial showed an 87% reduction in mean monthly HAE attacks. Cash balance stood at $628.4 million as of June 30, 2026, following a $195 million equity raise. R&D expenses declined to $82.6 million while G&A rose to $37.8 million due to commercial build-out.

Intellia Therapeutics grants 44,450 RSUs to new employees

Intellia Therapeutics granted 44,450 RSUs to eight new employees. Awards issued under the 2024 Inducement Plan as amended. RSUs vest annually over three years, one-third per year. Grants approved under Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics awards 163,100 RSUs to 41 new employees

Intellia Therapeutics awarded 163,100 RSUs to 41 new employees on September 1, 2026. Grants vest one-third annually over three years, contingent on continued service. Awards issued under the 2024 Inducement Plan as a material inducement to employment. Compensation committee approved the grants per Nasdaq Listing Rule 5635(c)(4).

Intellia Therapeutics secures $400M non-dilutive term loan from OrbiMed

Intellia Therapeutics secured a $400 million non-dilutive senior secured term loan from OrbiMed. Initial draw of $75 million funded at closing, with up to $225 million available via milestone-based tranches. Additional $100 million may be accessed subject to mutual agreement over the five-year term. Proceeds will support the US approval and launch of lonvo-z for hereditary angioedema. Financing preserves shareholder equity while advancing CRISPR pipeline development.